E.S. BODRYAGINA¹, D.R. AKBEROVA¹, K.D. ZOROB¹, T.A. KHAFIZOVA²

 ¹Kazan State Medical University, Kazan

2Republic Clinical Hospital, Kazan

 Contact details:

Bodryagina E.S. — PhD (medicine), Assistant Lecturer of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7 (843) 237-32-61, e-mail: snezenka@rambler.ru

The article presents a description of a clinical case of primary sclerosing cholangitis and Crohn’s disease combined in one patient. The onset of primary sclerosing cholangitis was observed during exacerbation of Crohn’s disease, which leads to basic therapy with corticosteroids and immunosupressors in combination with ursodeoxycholic acid. There are certain difficulties in managing comorbid patients with Crohn’s disease and extraintestinal manifestations.

Key words: Crohn’s disease, primary sclerosing cholangitis, azathioprine, ursodeoxycholic acid, extraintestinal manifestations.

REFERENCES

1. Klinicheskie rekomendatsii. Yazvennyy kolit [Clinical recommendations. Ulcerative colitis]. Rossiyskaya gastroenterologicheskaya assotsiatsiya, Assotsiatsiya koloproktologov Rossii. Ministerstvo zdravookhraneniya RF, 2020 g.
2. Klinicheskie rekomendatsii. Bolezn’ Krona [Clinical recommendations. Crohn’s disease]. Rossiyskaya gastroenterologicheskaya assotsiatsiya, Assotsiatsiya koloproktologov Rossii. Ministerstvo zdravookhraneniya RF, 2020 g.
3. Saich R., Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol, 2008, Jan 21, vol. 14 (3), pp. 331–337. DOI: 10.3748/wjg.14.331
4. Harbord M., Annese V., Vavricka S.R. et al. European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis, 2016, Mar, vol. 10 (3), pp. 239–254. DOI: 10.1093/ecco-jcc/jjv213
5. Dyson J.K., Beuers U., Jones D.E.J., Lohse A.W., Hudson M. Primary sclerosing cholangitis. Lancet, 2018, Jun 23, vol. 391 (10139), pp. 2547–2559. DOI: 10.1016/S0140-6736(18)30300-3
6. Weng M.T., Shih I.L., Tung C.C., Leong Y.L., Shieh M.J., Wang C.Y., Wong J.M., Ni Y.H., Wei S.C. Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease. Intest Res, 2022, Apr, vol. 20 (2), pp. 224–230. DOI: 10.5217/ir.2021.00042
7. Karlsen T.H., Folseraas T., Thorburn D., Vesterhus M. Primary sclerosing cholangitis — a comprehensive review. J Hepatol, 2017, Dec, vol. 67 (6), pp. 1298–1323. DOI: 10.1016/j.jhep.2017.07.022
8. Bodryagina E.S., Akberova D.R., Mukhametova D.D. et al. Gender differences and clinical features of diseases of the liver and biliary tract. Prakticheskaya meditsina, 2021, vol. 19, no. 4, pp. 93–98 (in Russ.).
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol, 2022 Sep, vol. 77 (3), pp. 761–806. DOI: 10.1016/j.jhep.2022.05.011
10. Lindor K.D., Bowlus C.L., Boyer J., Levy C., Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019 Jan, vol. 69 (1), pp. 394–419. DOI: 10.1002/hep.30145
11. Ivashkin V.T., Shirokova E.N., Maevskaya M.V. et al. Clinical recommendations of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver for the diagnosis and treatment of cholestasis. RZhGGK, 2015, vol. 2, pp. 41–57 (in Russ.).
12. Liberal R., Gaspar R., Lopes S., Macedo G. Primary biliary cholangitis in patients with inflammatory bowel disease. Clin Res Hepatol Gastroenterol, 2020, Feb, vol. 44 (1), pp. e5–e9. DOI: 10.1016/j.clinre.2019.05.002
13. Pazenko E.V., Raykhel’son K.L., Kondrashina E.A. et al. Features of the course of primary sclerosing cholangitis, combined with inflammatory bowel diseases. Eksperimental’naya i klinicheskaya gastroenterologiya, 2017, no. 146 (10), pp. 33–39 (in Russ.).